GLASGOW, Scotland, Sept. 20, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced the opening of its first Customer Experience Centre in Russia in partnership with Khimexpert, an authorized distributor of the company, providing customers with access to the latest cutting-edge technology.
Located in Moscow, the center is equipped with the most advanced genetic analysis systems and qualified experienced staff to perform the latest genetic, cell and molecular biology techniques, including next-generation sequencing. Each customer focused technical seminar will include instruction and hands-on time with the instruments.
"The Life Sciences in Russia are going through a dynamic transition and we look forward to opening this state-of-the-art Customer Experience Centre with our partners, Khimexpert," said Peter Silvester, President, Life Technologies Europe, Middle East & Africa. "We have already seen an overwhelming response from our customers who are keen to attend our seminars and lab demos, so it is already proving to be a popular facility."
Igor Merkulov, General Manager, Khimexpert said: "Khimexpert is very pleased to open this demo lab with such a long-term business partner. With technology advancing so quickly, our customers need a facility such as this to gain hands-on time and one-to-one guidance with product experts to get the full benefit from these technologies for their research."
It is also planned to expand the facility further in the future, to cover major instruments and workflows based on Life Technologies' world-class brands, such as Ambion®, Applied Biosystems®, Gibco®, Invitrogen™, Ion Torrent™, Molecular Probes® and Novex®.
A special launch event with presentations will be held at the new facility today at 3 p.m. Moscow Standard Time. Details are available on request.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Contact:
David Robertson, Leader, External Communications, EMEA, Life Technologies Contact